Publications

1502 Tubular-Infiltrative Variant of Acinar Cell Carcinoma: Clinicopathologic Analysis of 11 Cases of A Distinct Entity Invariably Misdiagnosed as Ductal Adenocarcinoma

D Bahceci, N Tezcan, B Memis, W Park, E O'Reilly, D Klimstra, O Basturk, ...

340O Safety and efficacy of zoldonrasib (RMC-9805) plus chemotherapy in patients (pts) with 1L RAS G12D metastatic pancreatic adenocarcinoma (MPDAC)

BM Wolpin, S Pant, A Spira, TB de Castria, GP Botta, V Florou, GA Manji, ...

342O Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in patients (pts) with claudin 18 isoform 2 (CLDN18. 2)+ metastatic pancreatic adenocarcinoma (mPAC): phase II GLEAM …

W Park, L Shen, MP Ducreux, S Mitsunaga, G Roth, B Shen, ...

425P Arterial thromboembolism in pancreatic ductal adenocarcinoma: A marker of advanced disease and poor survival

A Syal, K Yu, W Park, C O'Connor, M Capanu, J Chou, C Schwartz, ...

430P CLDN18. 2 and KRAS signaling shape tumor states and immune microenvironment in pancreatic cancer (PC)

V Nasca, M Hilmi, N Tezcan, M Perry, M May, J Song, F Balogun, ...

A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer

Alagesan B, Varghese AM, Ang C, Gutierrez M, Kamar M, Passhak M, Geva R, Yarom N, et al.

Abstract A042: ctDNA KRAS detection in pancreatic ductal adenocarcinoma: Platform concordance, sensitivity and clinical associations in a contemporary cohort

J Guo, M May, MF Berger, E Cismas, M Hilmi, A Singhal, F Balogun, ...

Abstract A050: Mutant allele copy number gains define distinct molecular subtypes of oncogene-driven cancers and are associated with response to allele-specific KRASG12C …

MA Perry, AL Richards, A Price, SE Tischfield, H Walch, H Xie, ...

Abstract A124: Prevalence, Treatment Patterns, and Outcomes of Organ Dysfunction at Diagnosis in Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Institution Analysis of 3 …

E Cismas, RB Forman, J Zheng, Q Shi, W Park, M Pishvaian, ...

Abstract B020: Myofibroblasts induce neuroplasticity to promote pancreatic inflammation and cancer progression

J Nigri, W Lan, ML Fung, C Kayser, A Deschênes, J Hinds, S Kaushalya, ...

Abstract LB407: Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC)

BM Wolpin, BL Musher, GA Manji, W Park, A Spira, N Azad, V Florou, ...

Abstract LB423: Invigorating pre-existing tumor-infiltrating expandable (TIE) T cell clonotypes in exceptional responders with dual PARP-PD-1 blockade in homologous …

M Hilmi, W Mckerrow, JD Schoenfeld, S Umeda, N Tezcan, C O'Connor, ...

Abstract PR014: Integrated translational analyses of the first generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offers rational …

W Park, S Kadam, A Kasi, T Macarulla, C Fountzilas, M Ueno, T Saito, ...

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer

Aronchik I, Kar S, Zhuang Y, Ahler E, Lai LP, Seshadri V, Yang YC, Bulle A, et al.

Anatomical dynamics define cancer cachexia subtypes and identify systemic inflammation as a marker of lethal wasting

Boscenco S, Castillon VJ, Wang J, Tse E, Freeman SS, Bakouny Z, Mohan S, Guo XA, et al.

ASO Visual Abstract: Outcomes of First-versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma

Nasar N, Armstrong M, Chou JF, Gonen M, Soares KC, Balachandran VP, Drebin JA, Kingham TP, et al.

Association of genomic and clinical factors with outcomes with front-line chemoimmunotherapy in patients with advanced biliary tract cancer.

OM Fitzpatrick, J Chou, J Xu, A Dhyani, DN Khalil, F Nagib, F Keane, ...

Biomarker and pharmacokinetics (PK) analyses of zolbetuximab from the phase 2 GLEAM study in patients (pts) with claudin 18 isoform 2 (CLDN18. 2)+ metastatic pancreatic …

W Park, L Shen, MP Ducreux, S Mitsunaga, G Roth, B Shen, ...

Characterization of antibody-drug conjugate target antigen expression in patients with biliary tract cancer.

A Dhyani, N Tezcan, J Chou, Z Tarcan, R Thummalapalli, F Nagib, ...

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer

Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, Punekar SR, et al., for the RMC-6236-001 Investigators

Deep Learning Enabled 3D Multi-Omic Analysis Reveals Molecular Signatures of Heterogeneous Response to Chemotherapy in Pancreatic Cancer

Forjaz A, Mojdeganlou H, Valentin A, Wetzel M, Lvovs D, Deshpande A, Shin SM, Piya S, et al.

Dual pancreatic carcinomas: clonally related or independent primaries?

Schoenfeld JD, Ravichandran V, Tarcan Z, Sahin-Ozkan H, Richards AL, Bilani N, Chou JF, O'Connor CA, et al.

Efficacy and safety of ASP3082 monotherapy or in combination with mFOLFIRINOX in patients (pts) with pancreatic ductal adenocarcinoma (PDAC).

A Kasi, CD Lopez, C Fountzilas, S Kitano, A Hollebecque, J Berlin, ...

Genomic and biomarker landscape of MTAP deficiency in gastrointestinal cancers.

R Thummalapalli, J Xu, N Tezcan, A Dhyani, OM Fitzpatrick, F Nagib, ...

Genomic evolution of pancreatic cancer at single-cell resolution

Zhang H, Sashittal P, Karnoub ER, Jakatdar A, Umeda S, Hong J, Noronha AM, Cardenas A 3rd, et al.

IL10R Inhibition Induces Neutrophil Tumoricidal Activity

Khalil DN, Gomez R, Regev A, Samaan F, Marouf Y, Budhu S, Hirschhorn D, Schulze I, et al.

Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial

Reyngold M, Wei AC, O'Reilly EM, D'Angelica MI, Kingham TP, Soares KC, Varghese AM, White C, et al.

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

Cowzer D, Walch H, Atri P, Shah F, Huq R, Thummalapalli R, Nagib F, Varghese A, et al.

Myofibroblasts Induce Neuroplasticity to Promote Pancreatic Inflammation and Cancer Progression

Nigri J, Lan W, Fung ML, Kayser C, Deschênes A, Hinds J, Kaushalya S, Pawlak SA, et al.

Neoantigen-reactive CD8+ T cell engagement marks exceptional survivors of pancreatic cancer

M Hilmi, JD Schoenfeld, W McKerrow, Y Elhanati, CA O'Connor, S Umeda, ...

Organotropic and genomic characterization of pancreatic neuroendocrine carcinoma.

S Wallam, CJ Kinslow, R Thummalapalli, AA Wallam, DP Horowitz, ...

Outcomes of First Versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma

Nasar N, Armstrong M, Chou JF, Gonen M, Soares KC, Balachandran VP, Drebin JA, Kingham TP, et al.

Pancreatic Cancer: Translating Tumor Biology into Actionability

Balogun FO, Sherman MH, Park W, Soares KC, Reyngold M, Schoenfeld JD, Singhal A, Iacobuzio-Donahue CA, et al.

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

W Park, CA O’Connor, JF Chou, M Hilmi, Z Tarcan, C Schwartz, M Larsen, ...

Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer: The POLAR Trial

Park W (Corresponding Author), O’Reilly E, et al.

Phase 1 evaluation of ASP3082, a first-in-class selective protein degrader, in patients (pts) with KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC …

W Park, A Kasi, JW Goldman, M Pelster, B Herzberg, AW Tolcher, AI Spira, ...

POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer

Park W, Umeda S, Hilmi M, O'Connor C, Sharma R, Tezcan N, Zhang H, Zhu Y, et al.

Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond

Schürmann H, Park W, O'Kane GM, Sciortino C, Niger M, Reichert M, Olive KP, Pretzell I, et al.

Prognostic value of CT radiomics in patients with gBRCA1/2 and PALB2 and advanced pancreas cancer.

S Gandhi, J Chakraborty, H Ghahremannezhad, R Do, N Horvat, KH Yu, ...

Safety and efficacy of daraxonrasib monotherapy as later-line (3L+) treatment for patients (pts) with metastatic pancreatic adenocarcinoma (PDAC).

I Garrido-Laguna, W Park, DS Hong, M Pelster, B Herzberg, AI Spira, ...

Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer

Park W, Kasi A, Spira AI, Paz-Ares Rodríguez L, Herzberg BO, Pelster MS, et al.

Target Antigen Identification for Antibody Drug Conjugate Therapy in Biliary Tract Cancer

A Dhyani, N Tezcan, JF Chou, Z Tarcan, R Thummalapalli, F Nagib, ...

Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer

Jiménez-Sánchez A, Persad S, Hayashi A, Umeda S, Sharma R, Xie Y, Mehta A, Park W, et al.

Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here

May MS, Park W, O'Reilly EM

Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here: MS May et al.

MS May, W Park, EM O’Reilly

Understanding the symptoms and impacts of living with metastatic pancreatic adenocarcinoma: a prospective, noninterventional qualitative study

Oh M, Chang L, Matney C, Fuldeore R, Perez E, Alici Y, Buzaglo J, Mao M, et al.

2137P ASP2138 monotherapy in patients (pts) with claudin 18 isoform 2 (CLDN18. 2)+, advanced solid tumors: phase I/Ib trial

K Shitara, HJ Choi, F Dayyani, S Kazmi, I Korakis, RH Moy, EM O'reilly, ...

261MO A phase II study of olaparib in patients (pts) with advanced biliary tract cancer (aBTC) with aberrant homologous recombinant repair (HRR) mutations

D Ahn, A Ulrich, W Park, S McCue, FS Ou, N Tran, LAK Fonkoua, ...

707 Mechanism of MLH1 inactivation predicts benefit to dual immune checkpoint blockade in mismatch repair deficient tumors

B Rousseau, V Randrian, K Sweeney, M Khushman, E Alouani, ...

Abstract A088: Genomic Scar to Immune Signals: Translational Insights from the POLAR Trial Reveal POLQ-Driven Immunogenicity in HRD Pancreatic Cancer

W Park, C O'Connor, M Hilmi, S Umeda, R Sharma, K Soares, ...